CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 61 enrolled
Drug / intervention
Verteporfin Photodynamic Therapy +1 moredrug
Likely dose
Verteporfin Photodynamic Therapy 6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00674323
NCT00674323Phase 4Completed
CompareCT.gov

A Multicentre, Randomized, Double Masked, Exploratory, Indocyanine Green Angiography (ICGA) Guided Study of 6 Months Duration to Compare the Safety and Effect on Polyp Regression of Verteporfin Photodynamic Therapy (PDT) Alone or Added to Ranibizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Novartis·interventional·Posted May 7, 2008·Updated Apr 19, 2011

In Brief

A Phase 4 clinical trial evaluating Verteporfin Photodynamic Therapy and Ranibizumab for Polypoidal Choroidal Vasculopathy. Completed, enrolled 61 participants across 5 sites in 5 countries.

Detailed Summary

This study aims to compare the efficacy of ranibizumab and verteporfin PDT combination treatment and verteporfin PDT monotherapy vs.ranibizumab monotherapy alone in achieving complete regression of polyps in patients with symptomatic macular polypoidal choroidal vasculopathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolypoidal Choroidal Vasculopathy
CountriesHong Kong, Singapore, South Korea, Taiwan, Thailand
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 7, 2008
Enrollment StartApr 1, 2008
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.2 years ago

Interventions

Verteporfin Photodynamic Therapydrug

After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.

Ranibizumabdrug

Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.